Lifecore signs agreement for commercial injectable program, revenue expected in 2028
AI Summary- Lifecore signed an agreement to transfer a marketed injectable product into its commercial manufacturing pipeline.
- The program is expected to generate commercial revenues in 2028 and become one of Lifecore’s largest contracts.
- The agreement is Lifecore’s seventh late-stage commercial program and 11th pipeline addition in 2026.